NATIONAL INSTITUTES OF HEALTH

MIT engineers have developed an implantable device that automatically administers glucagon to prevent life-threatening hypoglycemic episodes in diabetics, with testing in mice showing blood sugar stabilization within 10 minutes.

Scientists at The Herbert Wertheim UF Scripps Institute developed a novel antibody-drug conjugate combining tiancimycin, a natural compound from soil microbes, with a "double-decker" antibody targeting CD79b for diffuse large B cell lymphoma treatment.

UCLA-led researchers received a $3.5 million NIH grant to develop treatments for mpox, focusing on a more virulent strain causing increased deaths among children in the Democratic Republic of Congo.

The Indian Council of Medical Research (ICMR) and Panacea Biotec have initiated India's first Phase 3 clinical trial for an indigenous tetravalent dengue vaccine called DengiAll.

Quiver Bioscience received a $2.15 million Phase II SBIR grant from the National Institute of Neurological Disease and Stroke to develop an integrated platform for predicting safety of CNS-targeted antisense oligonucleotide therapeutics.

AN2 Therapeutics completed a 200-patient observational study in acute melioidosis, revealing a striking mortality rate of nearly 40% by Day 90 despite standard of care treatment.

The University of Kansas Medical Center received a five-year, $31 million NIH grant to coordinate pediatric clinical trials across 18 rural and underserved sites, marking the largest award in the institution's history.

University of Oxford researchers have developed a programmable microcapsule delivery system that enables complete malaria vaccination in a single injection, eliminating the need for booster visits.

TAM Global has appointed Dr. Francesco Marincola, one of the world's most prolific tumor immunologists with over 700 peer-reviewed publications, as Chief Scientific Officer across its expanding healthcare platform.

University of Wisconsin-Madison researchers have developed personalized cancer vaccines using pyroptotic vesicles, tiny sacs from dying cancer cells, that significantly extended survival in mouse models of triple-negative breast cancer and melanoma.